TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23907731

Group type: EXPERIMENTAL
Intervention: Serum B-type natriuretic peptide (BNP) test with a cutoff of >364 pg/mL
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Serum B-type natriuretic peptide (BNP) test with a cutoff of ≤ 182 pg/mL
Number of subjects: 218

Group type: COMPARATOR
Intervention: Serum-ascites albumin gradient (SAAG) and total protein concentration in ascites
Number of subjects: 218
Study: 23907766

Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI) at a maximum tolerated dose of 2.25 mg/m² once per week without a dose cap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI)
Number of subjects: 0
Study: 23908066

Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration Thrombectomy
Number of subjects: 202
Study: 23908179

Group type: EXPERIMENTAL
Intervention: Cone spacing measures
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cone density measures
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Direct, objective measures of cone structure
Number of subjects: 26
Study: 23908489

Group type: EXPERIMENTAL
Intervention: rHMPV-SHs
Number of subjects: 21
Study: 23909727

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFA) added to parenteral nutrition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no omega-3 PUFA)
Number of subjects: 80
Study: 23909991

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 161

Group type: COMPARATOR
Intervention: IVF and ICSI
Number of subjects: 161
Study: 23911539

Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for quantitation of chloroformate-derivatised amino acids, polyamines, and dipeptides
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa cell extract study
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Human urine study
Number of subjects: 332
Study: 23911702

Group type: COMPARATOR
Intervention: CD45-high group (CD45 expression above the 75th percentile)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: CD45-high group
Number of subjects: 1065
Study: 23912473

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 50-250 mg twice daily)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tapentadol treatment
Number of subjects: 63
Study: 23912587

Group type: EXPERIMENTAL
Intervention: Vaccination with whole leukemia cells (up to 6 vaccines initiated between days 30 and 45 after transplantation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vaccination with whole leukemia cells
Number of subjects: 22
Study: 23912763

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory strategies tested on the graft ex vivo during islet culture and/or on the graft site in vivo early after islet infusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available.
Number of subjects: 0
Study: 23913461

Group type: EXPERIMENTAL
Intervention: Normal Pd/Pa ratio (≥ 0.9)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Abnormal Pd/Pa ratio (< 0.9)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Normal rFFR (≥ 0.8)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Abnormal rFFR (< 0.8)
Number of subjects: 35
Study: 23913470

Group type: EXPERIMENTAL
Intervention: Vorinostat and niacinamide
Number of subjects: 24
Study: 23915179

Group type: EXPERIMENTAL
Intervention: LWWCOPD programme for pulmonary rehabilitation
Number of subjects: 57
Study: 23915426

Group type: EXPERIMENTAL
Intervention: Microarray-based TCMR score
Number of subjects: 264
Study: 23915500

Group type: EXPERIMENTAL
Intervention: AA homozygotes of rs2906569 (minor allele G, alternate allele A) at intron 1
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: CC homozygotes of rs2301963 (minor allele A, alternate allele C) at exon 3
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Combined frequency of rare missense variants
Number of subjects: 1111
Study: 23916058

Group type: EXPERIMENTAL
Intervention: Mind-body support group for patients with all cancer types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spiritual interventions incorporating spiritual values
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support through religious communities
Number of subjects: 0
Study: 23916583

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 65
Study: 23916692

Group type: EXPERIMENTAL
Intervention: Combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI
Number of subjects: 75
Study: 23917460

Group type: EXPERIMENTAL
Intervention: CYP phenotyping cocktail (50 mg tramadol, 20 mg omeprazole, 25 mg losartan, 200 mg caffeine) administered as a single oral dose.
Number of subjects: 22
Study: 23918740

Group type: EXPERIMENTAL
Intervention: Poor sleep quality (PSQI > 5)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Tobacco smokers
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patients with poor sleep quality
Number of subjects: 268

Group type: COMPARATOR
Intervention: Good sleep quality (PSQI ≤ 5)
Number of subjects: 268
Study: 23918838

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: HR75%, HR80%, HR85%, HRKarv0.6, HRKarv0.7, HRKarv0.8
Number of subjects: 212

Group type: COMPARATOR
Intervention: HRKarv0.7 or HR85%
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: HRKarv0.6 or HR80%
Number of subjects: 212
Study: 23919738

Group type: EXPERIMENTAL
Intervention: RESQ-7 (Reflux Symptom Questionnaire 7-day recall)
Number of subjects: 0
Study: 23920034

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 17
Study: 23921069

Group type: EXPERIMENTAL
Intervention: High intensity inspiratory muscle training (≥50% of Pi,max)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Low intensity inspiratory muscle training (≤10% of Pi,max)
Number of subjects: 170
Study: 23921878

Group type: EXPERIMENTAL
Intervention: Ultra low-dose OCP (1.0 mg norethindrone acetate and 10 micrograms ethinyl E2)
Number of subjects: 1660
Study: 23922111

Group type: EXPERIMENTAL
Intervention: High tumour expression of miRNA-126
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: EGFL7 expression at the invasive front
Number of subjects: 230
Study: 23922302

Group type: EXPERIMENTAL
Intervention: Post-olaparib chemotherapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 89
Study: 23924069

Group type: EXPERIMENTAL
Intervention: Previous TBI with LOC
Number of subjects: 586

Group type: COMPARATOR
Intervention: No previous TBI
Number of subjects: 586
Study: 23924590

Group type: EXPERIMENTAL
Intervention: 2010/11 seasonal, trivalent influenza vaccine (TIV)
Number of subjects: 55

Group type: COMPARATOR
Intervention: AS03 adjuvanted H1N1 vaccine
Number of subjects: 55
Study: 23924602

Group type: EXPERIMENTAL
Intervention: Exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <200 μg/g
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Severe exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <100 μg/g
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Incidence of steatorrhea
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Risk factors for EPI
Number of subjects: 563
Study: 23924639

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy sequencing after cessation of breastfeeding
Number of subjects: 0
Study: 23926193

Group type: COMPARATOR
Intervention: Follow-up I (July 2008 to June 2009)
Number of subjects: 11901

Group type: EXPERIMENTAL
Intervention: Follow-up II (July 2009 to April 2011) with newer technology
Number of subjects: 11901

Group type: EXPERIMENTAL
Intervention: Follow-up II (July 2009 to April 2011)
Number of subjects: 11901
Study: 23926234

Group type: EXPERIMENTAL
Intervention: 2D TVUS
Number of subjects: 99

Group type: COMPARATOR
Intervention: 2D MRI
Number of subjects: 99

Group type: COMPARATOR
Intervention: 3D MRI
Number of subjects: 99
Study: 23928873

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Self-reported compliance
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall therapeutic effectiveness
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Discontinuation rate
Number of subjects: 51
Study: 23929075

Group type: EXPERIMENTAL
Intervention: Hypo-osmolar 0.1% riboflavin solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iso-osmolar 0.1% riboflavin solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultraviolet-A irradiation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-treatment monitoring
Number of subjects: 18
Study: 23929784

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 50
Study: 23929927

Group type: EXPERIMENTAL
Intervention: Very low calorie ketogenic weight reduction diet with encouragement of exercise
Number of subjects: 6
Study: 23929949

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 5 doses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 4 doses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonvaccinated controls
Number of subjects: 40
Study: 23930209

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Everolimus 7.5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16
Study: 23932009

Group type: EXPERIMENTAL
Intervention: Placement of an uncovered, self-expandable, metal duodenal stent
Number of subjects: 108
Study: 23932335

Group type: EXPERIMENTAL
Intervention: Double negative for oestrogen- and progesterone receptors (ER/PR loss)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Pathologic expression of all markers
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: ER/PR loss in lymph node negative endometrioid tumours
Number of subjects: 832
Study: 23932458

Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ) administered at 8 visits
Number of subjects: 305
Study: 23934126

Group type: EXPERIMENTAL
Intervention: Mature DCs transfected with RNAs encoding melanoma antigens (MART1, MAGE-3, gp100, tyrosinase)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mature DCs transfected with siRNAs targeting the 3 inducible iP subunits (Arm C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mature DCs untransfected (Arm A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mature DCs transfected with control siRNA (Arm B)
Number of subjects: 12
Study: 23934268

Group type: EXPERIMENTAL
Intervention: Geographical clustering of STIs (chlamydia, gonorrhea, syphilis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial SaTScan Statistics software
Number of subjects: 0
Study: 23936059

Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (414.0 ± 25.5 ms)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (416.9 ± 22.6 ms)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (418.2 ± 24.8 ms)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mutations in major Long QT syndrome genes (SCN5A and KCNH2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mutations in a minor Long QT syndrome gene (KCNE2)
Number of subjects: 88
Study: 23936565

Group type: EXPERIMENTAL
Intervention: Dengue diagnosed by NS1 antigen positivity
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Dengue diagnosed by serology
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Chikungunya
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: S. Typhi
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Dengue-positive cases not clinically diagnosed
Number of subjects: 1500
Study: 23938372

Group type: EXPERIMENTAL
Intervention: Staging laparoscopy (S-LPS) before primary debulking surgery (PDS) or neoadjuvant treatment (NACT)
Number of subjects: 300
Study: 23939215

Group type: EXPERIMENTAL
Intervention: Low Risk Ankle Rule implementation (phases 2 and 3)
Number of subjects: 2151

Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Low Risk Ankle Rule (phases 2 and 3)
Number of subjects: 2151
Study: 23939283

Group type: EXPERIMENTAL
Intervention: Dose-dense ixabepilone (40 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dose-dense FEC (5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Number of subjects: 42
Study: 23939368

Group type: EXPERIMENTAL
Intervention: Oral Rapid Test (ORT)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Enzyme-Linked Immunosorbent Assay (ELISA)
Number of subjects: 497
Study: 23939898

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg every 12 h on day 1, followed by 200 mg every 12 h for 3 days)
Number of subjects: 12
Study: 23940128

Group type: EXPERIMENTAL
Intervention: Recombinant human PRL (r-hPRL) 60 μg/kg every 12 hours for 17 days
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1
Study: 23940282

Group type: EXPERIMENTAL
Intervention: Ibrutinib (PCI-32765)
Number of subjects: 0
Study: 23940592

Group type: EXPERIMENTAL
Intervention: Elderly individuals with a history of falls
Number of subjects: 161

Group type: COMPARATOR
Intervention: Elderly non-fallers
Number of subjects: 161
Study: 23940729

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 142
Study: 23941588

Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric thermal ablation (RFVTA)
Number of subjects: 124
Study: 23942767

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microvascular dysfunction (MVD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (PAH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combinations of two or three disorders
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous subset, kidney involvement, velocity of tricuspid regurgitation, diabetes mellitus
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MVD and CAD alone or in combination with PAH
Number of subjects: 120
Study: 23942857

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3746
Study: 23942908

Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anatomical MRI
Number of subjects: 40
Study: 23944301

Group type: EXPERIMENTAL
Intervention: Transcranial MRI-guided focused ultrasound thalamotomy
Number of subjects: 15
Study: 23945372

Group type: EXPERIMENTAL
Intervention: Larger ex vivo capsules in baseline CSF
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Capsule size
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: CSF capsule shedding
Number of subjects: 134
Study: 23947389

Group type: EXPERIMENTAL
Intervention: Switch antipsychotic plus healthy lifestyle education (HLE)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Add metformin plus healthy lifestyle education (HLE)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy lifestyle education (HLE) with no medication change
Number of subjects: 132
Study: 23947473

Group type: EXPERIMENTAL
Intervention: sRAGE levels in the TESRA cohort
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: sRAGE levels in the ECLIPSE cohort
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: SNP rs2070600
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: SNP rs2071288
Number of subjects: 410
Study: 23948110

Group type: EXPERIMENTAL
Intervention: Drug eluting balloon (DEB)
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Drug eluting stent (DES)
Number of subjects: 1462
Study: 23948301

Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Low Axillary Sampling (LAS)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Blue and/or Hot Nodes (B&/HN)
Number of subjects: 478
Study: 23949214

Group type: EXPERIMENTAL
Intervention: 150 IU HCG daily for 7 days
Number of subjects: 17
Study: 23950152

Group type: EXPERIMENTAL
Intervention: Testing for mutations in 12 disease genes (IMPDH1, KLHL7, NR2E3, PRPF3/RP18, PRPF31/RP11, PRPF8/RP13, PRPH2/RDS, RHO, RP1, TOPORS, RPGR, RP2) through PCR-based dideoxy sequencing.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Testing for mutations in autosomal genes.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Testing for mutations in X-linked genes.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Detection of distinct mutations.
Number of subjects: 170
Study: 23950178

Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 55
Study: 23952719

Group type: EXPERIMENTAL
Intervention: mTBI patients at 6 months
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: mTBI patients at 12 months
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: mTBI patients at 3 months
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: mTBI patients at 1 year
Number of subjects: 375
Study: 23953269

Group type: EXPERIMENTAL
Intervention: tolcapone (100mg/day titrated to 100mg thrice/day)
Number of subjects: 24
Study: 23953882

Group type: EXPERIMENTAL
Intervention: Cytarabine (10-20mg/m²/day for 14 days) + Vorinostat (400mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential arm (starting on day 14)
Number of subjects: 40
Study: 23953988

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (iv LCM) at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (iv LCM)
Number of subjects: 16
Study: 23954063

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 3489

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) for ISR
Number of subjects: 3489

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) for ISR
Number of subjects: 3489
Study: 23954335

Group type: EXPERIMENTAL
Intervention: Main vessel (MV) stenting
Number of subjects: 2227
Study: 23954889

Group type: EXPERIMENTAL
Intervention: Pomalidomide (2.5 mg/d), cyclophosphamide (50 mg every other day), prednisone (50 mg every other day) for 6 cycles, followed by maintenance therapy.
Number of subjects: 69
Study: 23955713

Group type: EXPERIMENTAL
Intervention: Anti-angiogenic therapy
Number of subjects: 0
Study: 23956613

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (WallFlex) for 6 months
Number of subjects: 23
Study: 23958335

Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention consisting of interactive learning activities conducted in workshops based on evidence-based knowledge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-equivalent control group, details not specified).
Number of subjects: 0
Study: 23958371

Group type: EXPERIMENTAL
Intervention: Referral letters from primary care to specialised mental health care
Number of subjects: 4

Group type: COMPARATOR
Intervention: General guidelines and guidelines for somatic care
Number of subjects: 4
Study: 23958434

Group type: EXPERIMENTAL
Intervention: Self-reported BMI (29.0±8.37 kg/m(2))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported height
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported BMI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported BMI category
Number of subjects: 60
Study: 23958949

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD)
Number of subjects: 0
Study: 23959571

Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 3057

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 3057
Study: 23959743

Group type: EXPERIMENTAL
Intervention: Geometric annuloplasty ring and leaflet reconstruction with concomitant sinus and ascending aortic graft replacement
Number of subjects: 6
Study: 23959756

Group type: EXPERIMENTAL
Intervention: Goal-directed early mobilisation intervention in the surgical ICU
Number of subjects: 200
Study: 23959883

Group type: EXPERIMENTAL
Intervention: Left hemisphere interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemisphere interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of lateralization
Number of subjects: 0
Study: 23961354

Group type: EXPERIMENTAL
Intervention: Patient assistance program information
Number of subjects: 333

Group type: COMPARATOR
Intervention: Department of Health pamphlet about breast cancer and treatment
Number of subjects: 333
Study: 23962071

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 610
Study: 23963055

Group type: EXPERIMENTAL
Intervention: Escalating doses of transdermal nicotine (mean NRT dose 32.7 mg/d; range, 7-56 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Escalating doses of transdermal nicotine
Number of subjects: 12
Study: 23965261

Group type: EXPERIMENTAL
Intervention: Motivational pharmacotherapy
Number of subjects: 50
Study: 23965279

Group type: EXPERIMENTAL
Intervention: Multimedia intervention with personalized health messages and health goal selection
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Multimedia intervention
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: MI and GRS reports
Number of subjects: 367
Study: 23965300

Group type: EXPERIMENTAL
Intervention: Personalized exercise intervention
Number of subjects: 39
Study: 23965778

Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 1813

Group type: COMPARATOR
Intervention: HIV-negative men
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: HPV types 16 and 18 among HIV-positive men
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: HPV types 52, 51, 16, 18, 35, and 66
Number of subjects: 1813
Study: 23965936

Group type: EXPERIMENTAL
Intervention: e-counselling
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control (general educational e-messages)
Number of subjects: 528